临床药物遗传学实施联盟 CYP2D6 基因分型和托莫西汀治疗指南
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
机构信息
Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, Minnesota, USA.
Department of Experimental and Clinical Pharmacology, College of Pharmacy, Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
出版信息
Clin Pharmacol Ther. 2019 Jul;106(1):94-102. doi: 10.1002/cpt.1409. Epub 2019 Apr 13.
Abstract
Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
摘要
阿托西汀是一种非兴奋剂药物，用于治疗注意力缺陷/多动障碍（ADHD）。细胞色素 P450（CYP）2D6 多态性影响阿托西汀的代谢，从而影响药物的疗效和安全性。我们总结了已发表文献中的证据，支持这些关联，并根据 CYP2D6 基因型（www.cpicpgx.org 上的更新）为阿托西汀提供治疗建议。
相似文献
1
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.临床药物遗传学实施联盟 CYP2D6 基因分型和托莫西汀治疗指南
Clin Pharmacol Ther. 2019 Jul;106(1):94-102. doi: 10.1002/cpt.1409. Epub 2019 Apr 13.
2
Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.托莫西汀药物遗传学：与药代动力学、治疗反应及耐受性的关联
Pharmacogenomics. 2015;16(13):1513-20. doi: 10.2217/PGS.15.93. Epub 2015 Aug 28.
3
CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.细胞色素P450 2D6（CYP2D6）预测的代谢状态与参与一项大型安慰剂对照的托莫西汀维持反应临床试验的成年注意缺陷多动障碍患者的安全性。
J Clin Pharmacol. 2015 Oct;55(10):1167-74. doi: 10.1002/jcph.530. Epub 2015 Jun 14.
4
Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.托莫西汀：关于其与药物处置相关的药代动力学和药物基因组学的综述。
J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26. doi: 10.1089/cap.2015.0137. Epub 2016 Feb 9.
5
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.单剂量、CYP2D6基因分型分层的托莫西汀在注意缺陷多动障碍儿童中的药代动力学研究。
Clin Pharmacol Ther. 2016 Jun;99(6):642-50. doi: 10.1002/cpt.319. Epub 2016 Jan 12.
6
Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.因 CYP2D6 活性低导致的阿托西汀代谢受损的识别。
Pediatr Neurol. 2010 Sep;43(3):159-62. doi: 10.1016/j.pediatrneurol.2010.04.004.
7
[A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder: genetic testing and therapeutic drug monitoring].[托莫西汀治疗注意缺陷多动障碍儿童的精准药物治疗研究：基因检测与治疗药物监测]
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Jan 15;25(1):98-103. doi: 10.7499/j.issn.1008-8830.2208092.
8
Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.评估 SLC6A2 和 CYP2D6 多态性对注意缺陷多动障碍中托莫西汀治疗的影响。
Eur J Clin Pharmacol. 2024 Nov;80(11):1773-1785. doi: 10.1007/s00228-024-03744-z. Epub 2024 Aug 19.
9
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.CYP2D6与患有注意力缺陷多动障碍的儿童及青少年对托莫西汀的临床反应
J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242-51. doi: 10.1097/01.chi.0000246056.83791.b6.
10
Clinical pharmacokinetics of atomoxetine.托莫西汀的临床药代动力学
Clin Pharmacokinet. 2005;44(6):571-90. doi: 10.2165/00003088-200544060-00002.
引用本文的文献
1
Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences.患有精神健康疾病的儿童和青少年的药物遗传学检测：真实世界经验
Pharmaceuticals (Basel). 2025 Aug 8;18(8):1170. doi: 10.3390/ph18081170.
2
Opportunities for Pharmacogenomics in Pediatrics: Prescribing Trends of Psychiatric Medications With Pharmacogenomic Implications at a Multistate Pediatric Health System.儿科药物基因组学的机遇：多州儿科健康系统中具有药物基因组学意义的精神科药物处方趋势
J Pediatr Pharmacol Ther. 2025 Apr;30(2):245-249. doi: 10.5863/1551-6776-30.2.245. Epub 2025 Apr 14.
3
Review: Child Psychiatry in the Era of Genomics: The Promise of Translational Genetics Research for the Clinic.综述：基因组学时代的儿童精神病学：转化遗传学研究对临床的前景。
JAACAP Open. 2024 Aug 9;3(2):157-170. doi: 10.1016/j.jaacop.2024.06.002. eCollection 2025 Jun.
4
Pharmaco-Multiomics: A New Frontier in Precision Psychiatry.药物多组学：精准精神病学的新前沿。
Int J Mol Sci. 2025 Jan 26;26(3):1082. doi: 10.3390/ijms26031082.
5
Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine.临床药物遗传学检测与应用：韩国检验医学学会2024年更新指南
Ann Lab Med. 2025 Mar 1;45(2):121-132. doi: 10.3343/alm.2024.0572. Epub 2024 Dec 17.
6
Decoding Pharmacogenomic Test Interpretation and Application to Patient Care.解读药物基因组学检测结果及其在患者护理中的应用。
J Am Coll Clin Pharm. 2024 Jun;7(6):581-588. doi: 10.1002/jac5.1958. Epub 2024 May 8.
7
Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?儿童注意力缺陷多动障碍中托莫西汀的精准药物治疗：如何确保为合适的人选择合适的剂量？
Front Pharmacol. 2024 Oct 29;15:1484512. doi: 10.3389/fphar.2024.1484512. eCollection 2024.
8
Dopamine Transporter and Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study.在哌甲酯和托莫西汀交叉研究中多巴胺转运体及基因与注意力缺陷多动障碍治疗反应的关系
J Child Adolesc Psychopharmacol. 2024 Dec;34(10):458-469. doi: 10.1089/cap.2024.0069. Epub 2024 Oct 10.
9
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.利用真实世界药物使用和基因型数据评估药物遗传学检测的价值。
Clin Pharmacol Ther. 2025 Jan;117(1):278-288. doi: 10.1002/cpt.3458. Epub 2024 Oct 4.
10
copy number determination using digital PCR.使用数字PCR进行拷贝数测定。
Front Pharmacol. 2024 Aug 14;15:1429286. doi: 10.3389/fphar.2024.1429286. eCollection 2024.
本文引用的文献
1
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians<sup/>.精神医学和神经医学中的治疗药物监测：《神经精神药理学治疗药物监测共识指南》（2017 年更新版）全面概述；临床医生的工具<sup/>。
World J Biol Psychiatry. 2018 Apr;19(3):162-174. doi: 10.1080/15622975.2018.1439595. Epub 2018 Mar 1.
2
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.神经精神药理学治疗药物监测的共识指南：2017年更新版
Pharmacopsychiatry. 2018 Jan;51(1-02):e1. doi: 10.1055/s-0037-1600991. Epub 2018 Feb 1.
3
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.临床药物遗传学实施联盟（CPIC）关于 CYP2D6 和他莫昔芬治疗的指南。
Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.
4
Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016.2016 年美国儿童和青少年父母报告的 ADHD 诊断患病率及相关治疗情况。
J Clin Child Adolesc Psychol. 2018 Mar-Apr;47(2):199-212. doi: 10.1080/15374416.2017.1417860. Epub 2018 Jan 24.
5
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.临床药物遗传学实施联盟（CPIC）指南：CYP2D6 基因型与昂丹司琼和托烷司琼的应用。
Clin Pharmacol Ther. 2017 Aug;102(2):213-218. doi: 10.1002/cpt.598. Epub 2017 Apr 6.
6
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.临床药物基因组学实施联盟指南（CPIC）：CYP2D6 和 CYP2C19 基因型与三环类抗抑郁药剂量：2016 年更新。
Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13.
7
Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers.健康志愿者中托莫西汀与安非他酮之间潜在的代谢介导药物相互作用的评估。
J Pharm Pharm Sci. 2016 Apr-Jun;19(2):198-207. doi: 10.18433/J3H03R.
8
Prediction of CYP2D6 phenotype from genotype across world populations.全球不同人群中基于基因型对CYP2D6表型的预测。
Genet Med. 2017 Jan;19(1):69-76. doi: 10.1038/gim.2016.80. Epub 2016 Jul 7.
9
Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.托莫西汀的生物转化特征及其对儿童剂量个体化的生理药代动力学（PBPK）模型开发的意义。
Drug Metab Dispos. 2016 Jul;44(7):1070-9. doi: 10.1124/dmd.116.069518. Epub 2016 Apr 6.
10
Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics.抗癫痫药物与新型抗抑郁药和新型抗精神病药之间具有临床意义的药代动力学药物相互作用。
Pharmacol Res. 2016 Apr;106:72-86. doi: 10.1016/j.phrs.2016.02.014. Epub 2016 Feb 16.
Zotero 插件